Lead Product(s): GNT0004
Therapeutic Area: Musculoskeletal
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2020
CDMO’s capacity to produce AAV materials at large-scale will support Genethon and Sarepta’s project to take micro-dystrophin to clinical trials this year.